Clinical safety and tolerability of losartan

This publication has 11 references indexed in Scilit:

• Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension
  Clinical Therapeutics, 1996
• Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension
  Clinical Therapeutics, 1996
• Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
  Clinical Pharmacology & Therapeutics, 1995
• Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension
  Clinical Therapeutics, 1995
• Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension*
  American Journal of Hypertension, 1995
• Signal transduction mediated by angiotensin II receptor subtypes expressed in rat renal mesangial cells
  Regulatory Peptides, 1993
• Angiotensin II Receptor Subtypes
  American Journal of Hypertension, 1992
• Nonpeptide Angiotensin II Receptor Antagonists
  American Journal of Hypertension, 1991
• The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence.
  Circulation Research, 1991
• Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.
  Circulation Research, 1991